Nutriband Inc. (NTRB)

Market Cap	55.26M
Revenue (ttm)	1.80M
Net Income (ttm)	-7.24M
Shares Out	11.10M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,849
Open	4.900
Previous Close	4.910
Day's Range	4.810 - 5.110
52-Week Range	2.220 - 9.600
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 11, 2024

About NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRB
• Website: https://www.nutriband.com

Financial Performance

In 2023, Nutriband's revenue was $2.09 million, an increase of 0.27% compared to the previous year's $2.08 million. Losses were -$5.49 million, 22.3% more than in 2022.